ORIGINAL RESEARCH ARTICLE

Appropriateness of Medication Prescribing in Hospitalized Older Adults in a Tertiary Teaching Hospital in the Philippines: A Cross-Sectional Study

Maria Stella T. Giron1 · Nelia P. Cortes-Maramba2

Published online: 4 June 2020
© The Author(s) 2020

Abstract

Background The prescribing of potentially inappropriate medication (PIM) is a major health problem among older adults because of the high risk of adverse drug events. The number of older adults in the Philippines is increasing, and little is known about medication prescribing in this population.

Objectives Our objective was to determine the prevalence of and factors associated with PIM in older patients admitted to a tertiary teaching hospital.

Methods This was a cross-sectional study of patients aged ≥60 years admitted to a tertiary teaching hospital over a 3-month period. We used version 2 of the STOPP (Screening Tool of Older Persons’ Prescriptions) criteria to identify PIM prescribing.

Results Included in this study were 328 older patients prescribed at least one medication; the median age was 65.5 years (interquartile range [IQR] 62–71), and 53.7% were women. The median number of medications prescribed was five (IQR 2–8). In total, 128 (39%) patients had at least one PIM, and the most common criterion was antimuscarinic/anticholinergic drug burden. PIM was significantly associated with polypharmacy (odds ratio 5.44; 95% confidence interval 1.54–19.20).

Conclusion The prevalence of PIM using STOPP version 2 was 39% in this sample of hospitalized older adults and was significantly associated with polypharmacy. There is a need to raise awareness about medication prescribing in the care and management of older patients.

1 Background

Older adults often present with chronic diseases and multiple comorbid conditions that require the prescription of a number of medications. Physiological changes brought about by aging may influence the pharmacokinetics and pharmacodynamics of medications and result in adverse drug reactions [1]. In addition, because older adults are often excluded from clinical trials, evidence is insufficient to guide prescribers on proper therapeutic decisions [2]. Prescribing for older adults therefore becomes a challenge and some prescriptions may not be appropriate.

Potentially inappropriate medication (PIM) has been defined as the prescription of medications for which the risks of potential adverse drug events (ADEs) outweigh the expected benefits in a patient [3]. PIM is an important public health problem because of the high prevalence and serious consequences in older adults [3]. Depending on the patient setting, PIM prevalence is reported to range from 18.5 to 82.6% in residential long-term care facilities [4], up to 98.2% in hospitals [5], and up to 86.2% [6] in primary care settings.
PIMs are associated with serious adverse events, such as falls [7], decreased quality of life [8] and ability to carry out activities of daily living [9], more frequent emergency visits and hospitalization [10, 11], and death [10]. Substantial medical expenditure has been reported with PIM [10].

To educate and aid clinicians in their choice of medications, explicit criteria for prescribing medications were developed [13, 14]. The STOPP (Screening Tool for Older Persons’ Prescriptions) criteria, published in 2008 and updated in 2014, were formulated through a Delphi consensus method by a multidisciplinary team of 18 experts in geriatric pharmacotherapy from Ireland and the UK [15]. The STOPP criteria have been extensively used in several countries from different continents in both research and varied clinical settings [16]. Intervention studies showed STOPP to be effective in improving the quality of medication prescribing, decreasing adverse drug reactions [17] and recognizing patients requiring hospitalization following PIM-related ADEs [14].

As in the rest of the world, the proportion of older adults in the Philippines is increasing. Currently, adults aged ≥60 years account for 7.3% of the population, and this is projected to increase to 14.2% by 2050 [18]. The country has a mixed health system made up predominantly of the private sector. Patient out-of-pocket expenditure was 53.7% for total health and 85% for medications in 2014 [19, 20]. Under Philippine law, only physicians are allowed to prescribe, and there is no gatekeeping mechanism; patients are free to choose their own physicians, even specialists [19]. Visits to multiple physicians can therefore lead to prescription of multiple medications and to PIM.

PIM has become a global healthcare problem, particularly among older adults. This is evidenced by the number of tools developed to detect PIMs and numerous studies examining the prevalence of PIMs and related consequences. However, information regarding PIM in the Philippines is lacking. Recognizing medication-related problems is an important step in providing safer health outcomes for older Filipino adults. This study aims to determine the prevalence of and factors associated with PIM in older adults hospitalized in a tertiary teaching hospital.

The study population comprised patients aged ≥60 years who presented to the emergency department between 1 January and 31 March 2015 and were subsequently admitted to the hospital. A cut-off age of ≥60 years was chosen based on the World Health Organization (WHO) definition of older adults [21]. We excluded patients who were severely ill, were admitted to the intensive or coronary care units, had stage 4 cancer, or had a “do not resuscitate” order because the special type of management required in these areas meant that inappropriate medications may have been given by necessity.

Data were gathered from medical charts based on a list obtained from the medical records section. Two registered pharmacists independently reviewed and collected information on age, sex, medical diagnoses, and medications prescribed from the admission notes of the medical records. The data were reviewed and verified by the authors.

Medical diagnoses were categorized according to the International Classification of Diseases and Related Health Problems, Tenth Revision [22], and disease severity was assessed using the Charlson Comorbidity Index (CCI) [23]. Medications were classified according to the Anatomical Chemical Therapeutic classification system recommended by the WHO [24]. Polypharmacy was defined as the prescription of five or more medications [25].

We used version 2 of the STOPP criteria to determine exposure to PIM. These criteria are based on 80 PIMs categorized by physiological systems that predispose older adults to ADEs, including drug–drug interactions and drug duplications [18]. All medications listed in the STOPP criteria were reviewed and are marketed in the Philippines.

2 Methods

2.1 Study Design, Setting, and Participants

This was a cross-sectional retrospective study conducted at a metropolitan tertiary teaching hospital in the Philippines. This study was approved by the Ethics Committee of the University of the Philippines Review and Ethics Board (2016-520-01).

\[\Delta\text{Adis}\]
3 Results

3.1 Subject Characteristics

The characteristics of the study population are shown in Table 1. The median age was 65.5 years (IQR 62–71), and 53.7% were female (Table 1). The number of medical diagnoses ranged from 1 to 12 (median 3; IQR 1–5), with the most common being hypertension (41.2%), heart failure (24.4%), atherosclerosis (21.6%), diabetes mellitus (20.4%), and cancer (17.1%). The median CCI score was one (IQR 0–2), and 22% had a score ≥2.

The number of prescribed medications ranged from 1 to 16 (median 5; IQR 2–8), with 198 (60.4%) patients prescribed five or more. The most commonly prescribed classes of medications were as follows: alimentary tract and metabolism (64.6%), cardiovascular system (56.7%), blood and blood-forming organs (49.1%), anti-infectives for systemic use (37.2%), and the nervous system (26.5%). Patients with PIM were significantly more likely to be prescribed medications for the cardiovascular system (atorvastatin, amlodipine, organic nitrates, captopril, and carvedilol), antithrombotics (acetylsalicylic acid, enoxaparin, and clopidogrel), and for constipation (lactulose) (Table 2).

3.2 Potentially Inappropriate Medication

Using STOPP version 2, we identified 146 PIMs in 128 (39.0%) patients: 87 (26.5%) patients had one PIM, 35 had two PIMs, five had three PIMs, and one had four PIMs. The most common criterion was antimuscarinic/anticholinergic drug burden (58.2%), followed by drugs affecting the central nervous system (11.6%), drugs that predictably increase the risk of falls (11.0%), and drugs affecting the cardiovascular system (10.3%) (Table 3). Diphenhydramine was the most commonly prescribed PIM (23.3%), followed by long-acting benzodiazepines and ranitidine (11% each), organic nitrates (10.3%), ipratropium bromide (9.6%), and neuroleptics (6.2%).

Age (OR 0.98; 95% CI 0.98–1.0) and sex (OR 0.82; 95% CI 0.53–1.53) were not associated with PIM, whereas polypharmacy (OR 11.1; 95% CI, 6.03–20.34) and increasing CCI (OR 1.83; 95% CI 1.49–2.23) were significantly associated with PIM (Table 4). Multivariate logistic regression analysis showed that the association between PIM and polypharmacy (OR 5.44; 95% CI 1.54–19.20) remained significant.

### Table 1 Characteristics of the study population

| Characteristic | N (%) |
|----------------|-------|
| Age, mean (IQR) | 65.5 (62–72) |
| Sex | |
| Female | 176 (53.7) |
| Male | 152 (46.3) |
| Diagnoses | |
| Hypertension | 135 (41.2) |
| Congestive heart failure | 80 (24.4) |
| Atherosclerosis | 71 (21.6) |
| Diabetes mellitus | 67 (20.4) |
| Cancer | 56 (17.1) |
| Hypertensive heart disease | 50 (15.2) |
| Coronary heart disease | 46 (14.0) |
| Chronic kidney disease | 40 (12.2) |
| Acute coronary syndrome | 35 (10.7) |
| Cerebrovascular disease | 31 (9.5) |
| Sepsis | 16 (4.9) |
| Benign prostatic hyperplasia | 15 (4.6) |
| CCI, median (IQR) | |
| 0 | 108 (32.9) |
| 1 | 115 (35.1) |
| 2 | 47 (14.3) |
| 3 | 38 (11.0) |
| 4 | 19 (5.8) |
| 5 | 3 (0.9) |
| Medications, median (IQR) | 5 (2–8) |
| 1–4 | 130 (39.6) |
| 5–9 | 138 (42.1) |
| ≥10 | 60 (18.3) |
| Therapeutic class (ATC) | |
| Alimentary and metabolism | 212 (64.6) |
| Blood and blood-forming organs | 161 (49.1) |
| Cardiovascular system | 186 (56.7) |
| Dermatologicals | 4 (1.2) |
| Genitourinary system | 30 (9.1) |
| Systemic hormonal preparations, excluding sex hormones | 47 (14.3) |
| Anti-infectives for systemic use | 122 (37.2) |
| Antineoplastic and immunomodulating agents | 29 (8.8) |
| Musculo-skeletal system | 14 (4.3) |
| Nervous system | 87 (26.5) |
| Antiparasitic products, pesticides and repellents | 0 |
| Respiratory system | 59 (18.0) |
| Sensory organs | 15 (4.6) |
| Various | 13 (4.0) |

Data are presented as N (%), unless otherwise indicated

ATC Anatomic Therapeutic Chemical classification system, CCI Charlson Comorbidity Index, IQR Interquartile range

© Adis
Discussion

This study showed that PIM, as identified by STOPP version 2, was prevalent in this sample of hospitalized older patients. Polypharmacy was significantly associated with PIM, and antimuscarinic/anticholinergic burden was the most common PIM.

The prevalence of PIM in this study was comparable to that reported in previous studies using STOPP version 2 in hospitalized older patients. PIM rates of 41.5% and 42.1% were reported in patients admitted to the medical department of a hospital in Spain [12] and to the Medical and Surgical Departments of a university hospital in Japan [26], respectively. The reported prevalences of PIMs in hospitalized older adults using the same version were higher in patients admitted to specialty wards of a tertiary hospital in Brazil (50%) [27], patients discharged from a geriatric teaching hospital in Belgium (56%) [28], patients discharged from a medical unit in the UK (59.1%) [29], cardiovascular patients admitted to a teaching hospital in Ethiopia (61.5%) [30], patients discharged from the cardiology and medicine departments of a university hospital in Albania (63%) [31], and patients requiring palliative care in a geriatric acute care hospital in Spain (88.5%) [32]. The timing of data collection (at admission or discharge), the units to which patients were admitted, and patient characteristics may have accounted for the discrepancies in PIM prevalence.

Polypharmacy was significantly associated with PIM, a finding similar to that in most PIM studies [24, 26, 27, 29]. Older patients are the largest consumers of medications because of multiple chronic conditions, multiple prescribers, and evidence-based guidelines recommending the use of more than one medication for the treatment of chronic conditions such as hypertension [33]. Multiple medications may be important in the management of multimorbid older patients, but it increases the risk of PIM and consequently the risk of ADE [17].

Most PIM studies in hospitalized older adults report that the most commonly prescribed PIMs are drugs affecting the central nervous system [11, 14, 26, 28]. In this study, the most common PIM criterion was antimuscarinic/anticholinergic drug burden. Diphenhydramine, a first-generation antihistamine, under the central nervous system criterion, was the second most common PIM. These two criteria have in common medications that possess anticholinergic properties. Our results present challenges concerning the risk of

---

### Table 2 The most frequently prescribed medications among patients with and without potentially inappropriate medication

| Medication       | With PIM N (%) | Without PIM N (%) | p value |
|------------------|----------------|-------------------|---------|
| Atorvastatin     | 73 (55.3)      | 43 (21.9)         | < 0.001 |
| Lactulose        | 54 (40.9)      | 30 (15.3)         | < 0.001 |
| Acetylsalicylic acid | 50 (37.9)    | 32 (16.3)         | < 0.001 |
| Clopidogrel      | 49 (37.1)      | 24 (12.2)         | < 0.001 |
| Omeprazole       | 44 (33.3)      | 53 (27.0)         | 0.22    |
| Enoxaparin       | 44 (33.3)      | 22 (11.2)         | < 0.001 |
| Amlodipine       | 44 (33.3)      | 0                 | < 0.001 |
| Organic nitrates | 44 (33.3)      | 11 (5.6)          | < 0.001 |
| Captopril        | 32 (24.2)      | 5 (2.8)           | < 0.001 |
| Carvedilol       | 28 (21.2)      | 12 (6.1)          | < 0.001 |

### Table 3 Potentially inappropriate medication prescribing identified by the STOPP criteria

| Criterion                                             | N (%) |
|-------------------------------------------------------|-------|
| Any duplicate drug class prescription                  | 5 (3.4)|
| Calcium channel blockers                               | 5 (3.4)|
| Cardiovascular system                                  | 15 (10.3)|
| Loop diuretic as first-line treatment                  | 11 (7.5)|
| Central nervous system                                 | 4 (2.7)|
| Central nervous system                                 | 17 (11.6)|
| Phenothiazines                                         | 1 (0.7)|
| First-generation antihistamines                        | 16 (11.0)|
| Respiratory system                                     | 3 (2.0)|
| Antimuscarinic bronchodilators with a history of bladder outflow obstruction | 3 (2.0)|
| Genitourinary system                                   | 2 (1.4)|
| Antimuscarinic drugs for chronic prostatism            | 2 (1.4)|
| Endocrine system                                       | 3 (2.0)|
| Sulphonylureas with a long duration of action           | 3 (2.0)|
| Drugs that predictably increase the risk of falls in older people | 16 (11.0)|
| Benzodiazepines                                        | 12 (8.2)|
| Neuroleptic drugs                                      | 4 (2.7)|
| Antimuscarinic/anticholinergic drug burden             | 85 (58.2)|

STOPP Screening Tool of Older Persons’ Prescriptions

### Table 4 Factors associated with potentially inappropriate medication prescribing

|                      | Unadjusted OR (95% CI) | p value | Adjusted OR (95% CI) | p value |
|----------------------|------------------------|---------|----------------------|---------|
| Age                  | 0.98 (0.98–1.0)        | 0.361   | 0.98 (0.94–1.02)     | 0.247   |
| Sex (female)         | 0.82 (0.53–1.53)       | 0.387   | 0.83 (0.49–1.38)     | 0.467   |
| CCI                  | 1.83 (1.49–2.23)       | < 0.001 | 1.14 (0.89–1.4)      | 0.287   |
| Polypharmacy         | 11.1 (6.03–20.34)      | < 0.001 | 5.44 (1.54–19.20)    | < 0.001 |

CCI Charlson Comorbidity Index, CI confidence interval, OR odds ratio

a Adjusted for age and sex

# Adis
prescribing anticholinergic medications and their adverse consequences. Older adults with concurrent multiple chronic diseases are prescribed medications for their anticholinergic activity and medications with unintended anticholinergic effects [34]. Because older adults have altered pharmacokinetics and pharmacodynamics, increased permeability of the blood–brain barrier, and multiple medications, they are very susceptible to the central and peripheral adverse effects of anticholinergic medications. A systematic review on the cumulative effects of anticholinergic medications reported an association with delirium, falls, physical and cognitive decline, and risk of dementia [35]. These consequences can lead to substantial burden of disease in older adults and a need for assistance with performing activities of daily living. Falls, cognitive decline, and dementia impose a substantial demand on health services and incur high healthcare costs. Physicians should be cognizant not only of the intended benefits but also, and more importantly, the adverse consequences of prescribing medications with anticholinergic properties in older adults.

This study examined the appropriateness of prescribing in older adults admitted to a tertiary teaching hospital in the Philippines. To the best of our knowledge, this is the first study on the appropriateness of medication prescribing using STOPP version 2 in hospitalized older patients in the Philippines. A previous study in another teaching hospital used the Beers 2012 criteria in older patients aged ≥65 years admitted to medical departments or to intensive care units and reported a higher PIM (49%) [36].

Our findings must be considered in light of some limitations. This study was conducted in a single tertiary teaching hospital, which precludes generalizability. A large prospective multicenter study is required to validate our findings. Data were collected retrospectively, no communication with physicians as to the rationale for prescribing a PIM was possible, and we may have underestimated the rate of PIMs not documented in medical records. Since the study was cross-sectional, causality of an association between the risk factors and PIM could not be established.

The results of this study convey the need to raise awareness about PIMs and educate healthcare professionals in the care and management of older patients. Lack of knowledge is reported to be the most common cause of prescribing error [37]. In the Philippines, only a handful of medical schools offer a course in geriatrics and geriatric medicine, as the specialty remains in its infancy. It was only in 2016 that the Commission on Higher Education, which is responsible for recommending policies and programs on higher education in the Philippines, included geriatric medicine in the medical curriculum [38]. Only a very few private hospitals in the country employ clinical pharmacists; in most hospitals, the pharmacist’s role is limited to medication dispensing. Therefore, clinical pharmacists need to be included in the patient’s healthcare team to collaborate with physicians in medication decision making and monitoring of patients for adverse drug reactions. Furthermore, adoption of electronic medical records in hospitals would enhance patient safety. Finally, the applicability of the STOPP criteria as a tool for education and prevention of ADRs should be investigated.

## 5 Conclusion

This study showed that PIM, using STOPP version 2, was prevalent in this sample of hospitalized older patients. The most common criterion was antimuscarinic/anticholinergic drug burden, and PIM was significantly associated with polypharmacy. We recommend that healthcare professionals are made aware of the problem of PIM and its consequences by providing the necessary education and in-depth training in prescribing for multimorbidity older patients.

### Author Contributions

Conceptualization, writing—original draft preparation, funding acquisition, resources, and supervision: MSTG. Methodology, formal analysis, investigation, and writing—review and editing: MSTG and NPC-M.

### Compliance with Ethical Standards

**Funding** The study was supported by a grant from the National Institutes of Health, University of the Philippines (grant no. NIH 2015-009), Manila.

**Conflicts of Interest** Maria Stella T. Giron and Nelia P. Cortes-Maramba have no conflicts of interest that might be relevant to the contents of this manuscript.

**Ethics Approval** This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments. Approval was granted by the Ethics Committee of University of the Philippines Review and Ethics Board (2016-520-01).

**Data Availability** The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

**Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
References

1. Corsonello A, Pedone C, Incalzi RA. Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem. 2010;17:571. https://doi.org/10.2174/092986710789216326.

2. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294(6):716–24. https://doi.org/10.1001/jama.2004.6.716.

3. Gallagher P, Barry P, O’Mahony D. Inappropriate prescribing in the elderly. J Clin Pharm Ther. 2007;32(2):113–21. https://doi.org/10.1111/j.1365-2710.2007.00793.x.

4. Storms H, Marquet K, Aertgeerts B, Claes N. Prevalence of inappropriate medication use in residential long-term care facilities for the elderly: a systematic review. Eur J Gen Pract. 2017;23(1):69–77. https://doi.org/10.1080/13814788.2017.1288211.

5. Galli TB, Reis WC, Andrzejevski VM. Potentially inappropriate prescribing and the risk of adverse drug reactions in critically ill older adults. Pharm Pract. 2016;14(4):818. https://doi.org/10.18549/pharmpract.2016.04.818.

6. Chang C-B, Yang S-Y, Lai H-Y, et al. Application of three different sets of explicit criteria for assessing inappropriate prescribing in older patients: a nationwide prevalence study of ambulatory care visits in Taiwan. BMJ Open. 2015;5:e008214. https://doi.org/10.1136/bmjopen-2015-008214.

7. Michalek C, Wehling M, Schlitzer J, et al. Effects of “Fit fOR The Aged” (FORTA) on pharmacotherapy and clinical endpoints—a pilot randomized controlled study. Eur J Clin Pharmacol. 2014;70:1261–7. https://doi.org/10.1007/s00228-014-1731-9.

8. Wallace E, McDowell R, Bennett K, et al. Impact of potentially inappropriate prescribing on adverse drug events, health related quality of life and emergency hospital attendance in older people attending general practice: a prospective cohort study. J Gerontol A Biol Sci Med Sci. 2017;72(2):271–7. https://doi.org/10.1093/gerona/glw140.

9. Tosato M, Landi F, Martone AM, Investigators of the CRIME Study, et al. Potentially inappropriate drug use among hospitalised older adults: results from the CRIME study. Age Ageing. 2014;43(6):676–73. https://doi.org/10.1093/ageing/afu029.

10. Lau DT, Kasper JD, Potter DEB, Lyles A, Bennett RG. Hospitalization and death associated with potentially inappropriate medication prescriptions among elderly nursing home residents. Arch Intern Med. 2005;165(1):68–74. https://doi.org/10.1001/archinte.165.1.68.

11. Gallagher P, O’Mahony D. STOPP (Screening Tool of Older Persons’ potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers’ criteria. Age Ageing. 2008;37(6):673–9. https://doi.org/10.1093/ageing/afn197.

12. Pardo-Cabello AJ, Manzano-Gamero V, Zamora-Pasadas M, et al. Potentially inappropriate prescribing according to STOPP-2 criteria among patients discharged from Internal Medicine: prevalence, involved drugs and economic cost. Arch Gerontol Geriatr. 2018;74:150–4. https://doi.org/10.1016/j.archgeriatr.2017.10.009.

13. Beers MH, Ouslander JG, Rollinger H, Reuben DB, Brooks J, Beck JC. Explicit criteria for determining inappropriate medication use in nursing home residents. Arch Intern Med. 1991;151(9):1825–32. https://doi.org/10.1001/archinte.1991.00400090107019.

14. Gallagher P, Ryan C, Byrne S, et al. STOPP (Screening Tool of Older Persons’ Prescriptions) and START (Screening Tool to Alert Doctors to Right Treatment): consensus validation. Int J Clin Pharm Ther. 2008;46(2):72–83.

15. O’Mahony D, O’Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in for people: version 2. Age Ageing. 2015;44(2):213–8. https://doi.org/10.1093/ageing/afu145.

16. O’Mahony D, Gallagher P, Ryan C, et al. STOPP & START criteria: a new approach to detecting potentially inappropriate prescribing in old age. Eur Geriatr Med. 2010;1:45–51. https://doi.org/10.1016/j.eurger.2010.01.007.

17. Hamilton H, Gallagher P, Ryan C, Byrne S, O’Mahony D. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med. 2011;171(11):1013–9. https://doi.org/10.1001/archinternmed.2011.215.

18. United Nations Department of Economic and Social Affairs. World Population Prospects. The 2015 Revision. https://esa.un.org/unpd/wpp/. Accessed 28 March 2018.

19. Dayrit MM, Lagrada LP, Picoz OF, Pons MC, Villaverde MC. The philippines health system review, vol. 8 no. 2. New Delhi: World Health Organization, Regional Office for South- East Asia; 2018. http://www.wpro.who.int/philippines/areas/health_systems/financing/philippines_health_system_review.pdf. Accessed 17 June 2019.

20. Clarete RL, Llanto GM. Access to medicines in the philippines: overcoming the barriers. Philippines Institute for Development Studies Poly Notes 2017. p. 2017–23. https://think-asia.org/bitstream/handle/11540/7967/pidspn1723.pdf?sequence=1. Accessed 17 June 2019.

21. Health statistics and information systems. Proposed working definition of an older person in Africa for the MDS Project. World Health Organization. https://www.who.int/healthinfo/survey/ageing/geron/docs older/en/. Accessed 30 Apr 2018.

22. World Health Organization. International Classification of Diseases 10th Revision (ICD-10). http://www.who.int/classifications/icd/ICD10Volume2_en_2010.pdf. Accessed 30 Apr 2018.

23. Charlson ME, Charlson RE, Peterson JC, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Clin Epidemiol. 2008;61(12):1234–40. https://doi.org/10.1016/j.jclinepi.2007.09.017-1.

24. World Health Organization. Anatomical therapeutic chemical (ATC) index with defined daily doses (DDDs). https://www.who.int/classifications/icd/ICD10_Volum e2_en_2010.pdf. Accessed 30 Apr 2017.

25. Masnoon N, Shabik S, Kalisch-Ellett L, et al. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17:230. https://doi.org/10.1186/s12877-017-0621-2.

26. Kimura T, Ogura F, Yamamoto K, et al. Potentially inappropriate medications in elderly Japanese patients: effects of pharmacists’ assessment and intervention based on Screening Tool of Older Persons’ Potentially Inappropriate Prescriptions criteria ver.2. J Clin Pharm Ther. 2017;42:209–14. https://doi.org/10.1111/jcpt.12496.

27. Juliano ACDSRS, Luccetti ALG, Silva JTSD, Santos LG, Nunes JBT, Fernandes GC, Luccetti G. Inappropriate prescribing in acutely ill older adults: a comparison of medical specialties. J Am Geriatr Soc. 2018;66:383–8. https://doi.org/10.1111/jgs.15138.

28. Sennesael A, Dalleur O, Henrard S, et al. Implementing a screening tool to improve prescribing in hospitalized older patients: a pilot study. Int J Clin Pharm. 2018;40:15–9. https://doi.org/10.1007/s11096-017-0563-y.

29. Counter D, Millar JWT, McLaw JS. Hospital readmissions, mortality and potentially inappropriate prescribing: a retrospective study of older adults discharged from hospital. Br J Clin Pharmacol. 2018;84(8):1757–63. https://doi.org/10.1111/bcp.13607.
30. Abegaz TM, Birru EM, Mekonnen GB. Potentially inappropriate prescribing in Ethiopian geriatric patients hospitalized with cardiovascular disorders using START/STOPP Criteria. PLoS One. 2018;13(5):e0195949. https://doi.org/10.1371/journal.pone.0195949.

31. Hudhra K, Beçi E, Petrela E, et al. Prevalence and factors associated with potentially inappropriate prescriptions among older patients at hospital discharge. J Eval Clin Pract. 2016;22(2):189–93. https://doi.org/10.1111/jep.12521.

32. Sevilla-Sánchez D, Molist-Brunet N, Amblàs-Novellas J, et al. Potentially inappropriate medication at hospital admission in patients with palliative care needs. Int J Clin Pharm. 2017;39:1018–30. https://doi.org/10.1007/s11096-017-0518-3.

33. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20. https://doi.org/10.1001/jama.2013.284427.

34. Gerretsen P, Pollock BG. Drugs with anticholinergic properties: a current perspective on use and safety. Expert Opin Drug Saf. 2011;10(5):751–65. https://doi.org/10.1517/14740338.2011.579899.

35. Cardwell K, Hughes CM, Ryan C. The association between anticholinergic medication burden and health related outcomes in the ‘oldest old’: a systematic review of the literature. Drugs Aging. 2015;32:835–48. https://doi.org/10.1007/s40266-015-0310-9.

36. Iturralde HP, Cortez RM. The prevalence of potentially inappropriate medications prescribed in elderly patients admitted in a tertiary teaching hospital: a retrospective cross-sectional study. Philipp J Int Med. 2017;55:1–6.

37. Velo GP, Minuz P. Medication errors: prescribing faults and prescription errors. Br J Clin Pharmacol. 2009;67(6):624–8. https://doi.org/10.1111/j.1365-2125.2009.03425.x.

38. Commission on Higher Education. Policies, Standards and Guidelines for the Doctor of Medicine (M.D.) Program. Commission on Higher Education Memorandum Order 16. https://ched.gov.ph/wp-content/uploads/2017/10/CMO-18-s.-2016.pdf. Accessed 20 Mar 2018.